Results 141 to 150 of about 22,842 (183)
Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis. [PDF]
BMC MedWu Y +19 more
europepmc +1 more source
Protective Effect and Mechanism of Rosiglitazone in α-amanitin-induced Hepatotoxicity Via Activation of PPAR-γ/Nrf2 Signaling Pathway. [PDF]
J Biochem Mol ToxicolLai F +8 more
europepmc +1 more source
Machine learning driven diabetes care using predictive-prescriptive analytics for personalized medication prescription. [PDF]
Sci RepZargoush M +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 1999
Rosiglitazone, a thiazolidinedione antidiabetic agent, improves insulin resistance, a key underlying metabolic abnormality in most patients with type 2 (non-insulin-dependent) diabetes mellitus. In animal models of insulin resistance, rosiglitazone decreased plasma glucose, insulin and triglyceride levels and also attenuated or prevented diabetic ...
J A, Balfour, G L, Plosker
+6 more sources
Rosiglitazone, a thiazolidinedione antidiabetic agent, improves insulin resistance, a key underlying metabolic abnormality in most patients with type 2 (non-insulin-dependent) diabetes mellitus. In animal models of insulin resistance, rosiglitazone decreased plasma glucose, insulin and triglyceride levels and also attenuated or prevented diabetic ...
J A, Balfour, G L, Plosker
+6 more sources
Expert Opinion on Pharmacotherapy, 2001
Type 2 diabetes mellitus is characterised by impaired insulin secretion, diminished peripheral insulin action and increased hepatic glucose production. Clinical trials have indicated that near-normal glucose control may reduce the risk for microvascular and - to a lesser extent - macrovascular complications in Type 2 diabetic patients ...
Wolffenbuttel, B.H.R. +2 more
openaire +4 more sources
Type 2 diabetes mellitus is characterised by impaired insulin secretion, diminished peripheral insulin action and increased hepatic glucose production. Clinical trials have indicated that near-normal glucose control may reduce the risk for microvascular and - to a lesser extent - macrovascular complications in Type 2 diabetic patients ...
Wolffenbuttel, B.H.R. +2 more
openaire +4 more sources
Drugs, 2005
The thiazolidinedione rosiglitazone and the biguanide metformin are effective antihyperglycaemic agents with different modes of action; rosiglitazone primarily increases insulin sensitivity, whereas metformin primarily reduces hepatic glucose output. Antihyperglycaemic combination therapy is often required to achieve effective glycaemic control.
openaire +2 more sources
The thiazolidinedione rosiglitazone and the biguanide metformin are effective antihyperglycaemic agents with different modes of action; rosiglitazone primarily increases insulin sensitivity, whereas metformin primarily reduces hepatic glucose output. Antihyperglycaemic combination therapy is often required to achieve effective glycaemic control.
openaire +2 more sources